Lixisenatide: Uses, Mechanism, and Side Effects

Managing blood sugar in type 2 diabetes often means combining more than one type of medication. Lixisenatide is the GLP-1 receptor agonist component of a combination product used alongside diet and exercise to help adults reach glycemic targets.

Key takeaways

• Lixisenatide is formulated with insulin glargine in the approved product Soliqua 100/33.
• It is indicated as an adjunct to diet and exercise for glycemic control in adults with type 2 diabetes.
• The label does not carry a boxed warning.
• More than 75 registered trials have studied lixisenatide, including head-to-head comparisons with other diabetes drugs.
• FAERS reports are dominated by product handling issues and blood glucose changes rather than classic drug reactions.

What Lixisenatide Is

Lixisenatide belongs to the GLP-1 receptor agonist class, while its partner ingredient, insulin glargine, is a long-acting insulin analog. Insulin lowers blood glucose by helping muscle and fat tissue take up glucose and by reducing glucose production in the liver. Together, the two components target blood sugar through complementary pathways in a single injectable product.

What Lixisenatide Is Approved For

Under the brand name Soliqua 100/33, lixisenatide combined with insulin glargine is approved to improve glycemic control in adults with type 2 diabetes, used alongside diet and exercise. The label specifies limitations of use: it is not recommended with other GLP-1 receptor agonist products, it is not intended for diabetic ketoacidosis, and it has not been studied together with prandial insulin. No boxed warning is present on this label.

What the Evidence Shows

Lixisenatide has been studied in 77 registered clinical trials. One completed Phase 3 trial compared the insulin glargine/lixisenatide fixed-ratio combination to lixisenatide alone as an add-on to oral antidiabetic drugs in patients in Japan. Another completed Phase 3 trial evaluated lixisenatide against sitagliptin as an add-on to metformin in obese patients with type 2 diabetes younger than 50.

Reported Side Effects

FAERS data reflect reported cases, not confirmed incidence or proven causation, and can include use outside the approved label. The largest categories involve blood glucose increases (460 reports) and product handling problems such as storage errors (400), off-label use (325), and accidental or skin exposure to the product (323 and 186, respectively). Gastrointestinal and other effects were also reported, including nausea (151), inappropriate dosing schedule (146), and visual impairment (145).